Dataset from A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006851
下载链接
链接失效反馈官方服务：
资源简介：
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17
years with ADHD decreases symptoms of ADHD.
创建时间：
2026-03-25
